A REVIEW ON THE NOVEL CORONA VIRUS WITH INTERNATIONAL AND INDIAN PERSPECTIVE

Authors:Dr Gayatri Suresh K P\*,Dr Thabit Ahmed\*\*, Dr Mohamed Abdelgadir Mohammed Saeed\*, Dr Jereish Varghese Daivamthadathil\*, Anandu Jayan\*\*\*, Jerin Reji Samuel\*\*\*

\*PharmD Interns

\*\*Cardiologist, Consultant

\*\*\*PharmD students

Bangalore Baptist Hospital, Bellary road,

Bangalore, Karnataka

Abstract

On 31 December 2019, pneumonia of unknown cause was detected in Wuhan, China, and was first reported to the WHO Country Office in China. On 30 January 2020, the outbreak was declared a Public Health Emergency of International Concern. (1)

It was an outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection that occurred in Wuhan, Hubei Province, China and got spread across China and beyond. WHO officially named the disease - Corona virus Disease 2019 (COVID-19) on February 12, 2020. (2)

It has been spreading worldwide for a period of atleast a year & half (3) This review article addresses the current scenario caused by the SARS- Co V along with the treatment protocols and ongoing vaccines.

Key words

Corona virus,COVID-19, m RNA, current therapy, vaccines, clinical symptoms, review

Introduction

Common flu and Covid 19

Corona viruses as the name suggests are called so due to the crown-like projections on their surfaces. "Corona" in Latin means "halo" or "crown." first identified in the 1960s, followed by SARS-Co V IN 2003, HCo V- NL63 in 2004, HKU1 in 2005, MERS-CoV in 2012 respectively. The human corona viruses are currently classified as seven types, which include, HCoV-229E, HCoV-OC43, HCoV-NL63, SARS-CoV, HKU1, MERS-CoV and 2019-nCoV. The corona virus (MERS-CoV and SARS-CoV) are more dangerous among all the corona virus. (4) COVID-19 and influenza have a similar clinical presentation since they both cause respiratory disease and primarily both viruses are transmitted by contact, droplets and fomites(5)(6)

SARS CoV-2

Corona viruses have naturally and evolutionarily, shaped and hosted by the bats. Indeed, it is postulated that most of the corona viruses that are found in humans are derived from the bat reservoir. (7)The recent studies have confirmed the genetic similarity of SARS-CoV-2 and a bat beta corona virus of the sub-genus Sarbecovirus. (7)(8)

|  |  |  |  |
| --- | --- | --- | --- |
| SIGNS AND SYMPTOMS | COLD | FLU ([INFLUENZA](https://www.medicinenet.com/influenza/article.htm)) | [COVID-19](https://www.medicinenet.com/wuhan_coronavirus_2019-ncov_symptoms_and_signs/symptoms.htm) ([WUHAN CORONAVIRUS](https://www.medicinenet.com/wuhan_coronavirus_2019-ncov/article.htm)) |
| Fever | Mild if present | Often | Often |
| [Fatigue](https://www.medicinenet.com/fatigue/article.htm), [Tiredness](https://www.medicinenet.com/fatigue/article.htm) | Occasional, mild | Common | Occasional |
| [Sneezing](https://www.medicinenet.com/sneezing/symptoms.htm) | Common | Infrequent | Infrequent |
| Body Aches | Common | Common | Occasional |
| [Headache](https://www.medicinenet.com/headache/article.htm) | Very infrequent | Common | Occasional |
| [Sore Throat](https://www.medicinenet.com/sore_throat_pharyngitis/article.htm) | Common | Occasional | Occasional |
| Stuffy or [Runny Nose](https://www.medicinenet.com/runny_nose/symptoms.htm) | Common | Occasional | Infrequent |
| [Diarrhoea](https://www.medicinenet.com/diarrhea/article.htm) | No | Occasional | Infrequent |
| [Watery eyes](https://www.medicinenet.com/watery_eye/symptoms.htm) | Common | Common | Infrequent |
| [Cough](https://www.medicinenet.com/chronic_cough/article.htm) | Mild | Dry cough | A dry cough, often severe |
| [Shortness of Breath](https://www.medicinenet.com/shortness_of_breath/symptoms.htm) | No | Rare | With mild/moderate infection |


The genome sequence of the novel corona virus is 96.2% similar to the bat SARS-related coronavirus (SARSr-CoV; RaTG13) collected from Yunnan province, China, but is not similar to the genomes of SARS-CoV (about 79%) or MERS-CoV (about 50%) [1, 15]. It is been confirmed that the SARS-CoV-2 uses the same receptor, the angiotensin-converting

enzyme II (ACE2), same as that of SARS-CoV. But the route of transmission from natural reservoirs to humans remains blinded, studies have been showing the pangolins providing a partial spike gene to SARS-CoV-2. (the crucial functional sites in the protein of SAR-CoV-2 are identical to one of the viruses that were isolated from a pangolin). (7)(9)

Etiology and pathophysiology

CoVs are positive-stranded RNA viruses that have a spikey appearance due to the presence of glycoproteins on the outer surface. It belongs to the family   *Coronaviridae*, which has the subclass *Orthocoronavirinae* that classifies the viruses into four genera of CoVs that include Alphacoronavirus (alphaCoV), Betacoronavirus (betaCoV), Deltacoronavirus (deltaCoV), and Gammacoronavirus (gammaCoV). (10)(11)

The  SARS-CoV-2 belongs to the betaCoVs category. It has a round/elliptical structure with a pleomorphic form. It has a diameter of 60–140 nm. This novel corona virus is sensitive to ultraviolet rays and heat and also these viruses can get inactivated by lipid solvents that include ether (75%), ethanol, chlorine-containing disinfectant, peroxyacetic acid and chloroform except for chlorhexidine. (10)

(12)

Virion structure

Coronavirus virus mainly contains 4 structural proteins,i.e spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, which are all encoded within the 3′ end of the viral genome.

*S protein*

The S protein with a mass of∼150 kDa uses N-terminal signal sequence to gain access to the ER and is heavily N-linked glycosylated. The spikey structure on the surface of the virus is due to the encodement of the homotrimers. (11)(13). It is a trimeric S glycoprotein that is a class I fusion protein which mediates the attachment to the host receptor. In some coronaviruses, S is cleaved by a host cell into two separate polypeptides noted S1 and S2. S1 forms the large receptor-binding domain of the S protein and S2 forms the stalk of the spike molecule. (11)

*M protein*

It is small in mass with ∼25–30 kDa and has 3 transmembrane domains and is observed to give the virion its shape. (11)

*E protein*

The E protein has a mass of ∼8–12 kDa and is found in small quantities. E protein in coronaviruses are specifically different but have a common architecture. The significant topology of E protein is not completely studied but data suggest that it is a transmembrane protein. (11)

Patients infected with COVID-19 had higher leukocyte numbers, high blood levels of cytokines and chemokines, increased levels of plasma pro-inflammatory cytokines and abnormal respiratory findings. The common symptoms included dry cough, coarse breathing sounds of both lungs, body temperature, fever , sore throat and fatigue. (14)

The pathogenesis of COVID-19 infection being a respiratory system targeting virus is considered to be severe pneumonia, RNA anaemia, along with the incidence of ground-glass opacities, and acute cardiac injury. (15)

Clinical presentation and transmission

Incubation period

The incubation period for COVID-19 is observed to vary between 7-14 days, with a median time of 4-5 days from exposure to symptoms onset. Certain studies have reported 97.5% of patients with COVID-19 are developing symptoms within 11.5 days of SARS-CoV-2 infection. (16)

Clinical symptoms

The prevalence of symptoms of COVID 19, based on over 55,000 lab cases shows fever(88%) , dry cough(67%),sore throat (14%) and fatigue(38%).COVID 19 is more contagious and less severe when compared to other SARS & MERS.(14)

Implications of mutations on the virus


Over a period of 1year & 6 months, 1200 variants of the novel corona virus has been identified, of which 1000 strains have been studied. (17)The current scenario rates to 11 mutations per sample, that accounts for more than the national average (8.4) and global average(7.3).(18)

The scientists have observed three major mutations of the COVID-19 virus so far:

* D614G
* VUI2020-12/01
* N501Y

D614G was responsible for the fast spread of the virus in Europe, the US and the rest of the world. VUI 2020-12/01 and N501Y are the current ones spreading in the UK.And the 'South Africa drift', where three mutations happened in the genetic make up of the virus.(19)Also,B.1.167 Covid variant being recogonised as Singapore strain is belived to affect the younger children.(20)

Currently the exponential increase of the cases in India is attributed to the mutations -L452R, E484Q, and P681R. with other mutations being recoginsed over as:



Another variant Delta (B.1.617.2), that belongs to a viral lineage first recognised in India during the second wave, that seemed to be around 60% more transmissible than the already highly infectious Alpha variant (also called B.1.1.7). Delta is found to be partially resistant to vaccines, A study published on 22 May found that a single dose of either AstraZeneca's or Pfizer's vaccine reduced a person’s risk of developing COVID-19 symptoms caused by the Delta variant by 33%, compared to 50% for the Alpha variant. A second dose of the AstraZeneca vaccine boosted protection against Delta to 60% (compared to 66% against Alpha), while two doses of Pfizer’s jab were 88% effective (compared to 93% against Alpha).(21)(22)

Treatment approaches & failure

*Lopinavir and Ritonavir*

Lopinavir and ritonavir (Kaletra) was given to those adult patients with laboratory-confirmed SARS-CoV-2 infection with certain criteria were eligible to receive lopinavir/ritonavir for 14 days after being confirmed with (i) respiratory distress with respiratory rate ≥22/min or SpO2 of <94 per cent; (ii) lung parenchymal infiltrates on chest X-ray; (iii) hypotension defined as systolic blood pressure <90 mmHg or need for vasopressor/inotropic medication; (iv) new-onset organ dysfunction, (v) age >60 yr, diabetes mellitus, renal failure, chronic lung disease and immune-compromised patients. Patients were monitored to document clinical, laboratory and safety outcomes. (23)

*Failure*

In few of the studies conducted it is concluded that in hospitalized adult patients with severe Covid-19, there was no benefit with lopinavir-ritonavir treatment beyond standard care. (24) Also according to the literature, it states that there was no significance in the treatment of Kaletra with COVID-19, only that there was an improvement of 1 day earlier of recovery. (25)

*Tocilizumab*

Recommended the use of **tocilizumab** as a single intravenous dose of 8 mg/kg of actual body weight which can be increased up to 800 mg given  **in combination with dexamethasone** (6 mg daily)in certain hospitalized patients who are exhibiting rapid respiratory decompensation due to COVID-19.

*Failure*

Tocilizumab (Actemra) did not reduce severe respiratory symptoms, intensive care visits, or death any better than standard treatments, the Italian Medicines Agency. (26)

*Remdesivir*

recommended using remdesivir for patients who were on high-flow oxygen, mechanical ventilation, or ECMO.(27)

*Failure*

studies reports that in patients with covid 19 who were administered with remdesivir, the patients’ developed bradycardia along with signs of worsening QT interval. This reverted upon stopping remdesvir therapy. The prevalence of bradycardia with prolonged QT interval is not well-known yet with this medication.(28)

*Ivermectin*

Studies done in vitro suggested that ivermectin acts by inhibiting the host importin alpha/beta-1 nuclear transport proteins, that is a vital intracellular transport process where viruses hijack to enhance infection thereby suppressing the host’s antiviral response and also ivermectin avts by interfering with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human cell membrane. Ivermectin is said to be host-directed on the basis of its broad-spectrum activity in vitro against the viruses that cause other major vitral infections.there are also some studies shows that ivermectin has a potential anti-inflammatory property, which has been postulated to be beneficial in people with COVID-19.(29)

*Failure*

The small size of the study, the unclear treatment arm assignments, and the lack of accounting of disease severity at baseline make it difficult to draw conclusions about the efficacy of using IVM to treat patients with mild COVID-19.(30)

Current treatment

|  |  |  |  |
| --- | --- | --- | --- |
| TREATMENT | DRUGS | DOSES | SPECIAL CONSIDERATIONS/FEATURES |
| Tab Hydroxychloroquine | T. HCQ (In high risk patients – DM / HTN / CVA / CKD / CLD / Obesity / Age > 60 yrs) | Day 1 - 400 mg BD Followed by 400 mg OD x 4 Days | avoid in cardiac disease or if QTc > 480 ms |
| Antibiotics | Tab Azithromycin | 500mg OD FOR 5 days | In case azithromycin is contraindicated-  T. AmoxClav 625 BD |
|  | T. Azithromycin  +  Inj. Piptaz  OR  Inj meropenem | 500 mg OD x 5 Days  +  4.5 mg  OR  500mg IV | In case of suspected secondary bacterial infection. |
| Routine | T. Paracetamol  Anti-tussives  T. Vitamin C  T. Zinc  C. Omeprazole/  Inj Pantoprazole | 500mg  SOS  500mg OD  50mg BD  20mg BD/  40mg OD | With adequate hydration with conservative fluids.  Oxygen maintenance: Maintain Target SPo2 > 90 % NRM (10 -15 lit / min) ↓ HFNC (10 - 60 lit / min) ↓ CPAP (TV 6ml/kg; PEEP 5-15 cm H20; Target PP 30 cm H20) ↓ MV (ARDS Protocol) |
| Anticoagulants | Inj enoxaparin | 40 mg SC OD x 5 Days | can be started as prophylactic without D DIMER.  Contraindicated in ESRD, active bleeding, emergency surgery, platelets < 20,000/mm3 , BP > 200/120) Inj. Dalteparin 2500 IU SC OD ×5 days |
| Monoclonal antibodies | tolicizumab | 400 mg (max 800 mg) slow IV in 100 ml NS/ 1 Hour | Contra Indications – Active Infections, TB, Hepatitis, Platelets < 1L/mm3 , ANC < 2000/mm3 |
| Steroids | Dexamethazone  inj. Methyl Prednisolone | 0.1 – 0.2 mg /kg ≈ 6 mg IV OD x 5 Days  1.0 -2.0 mg/kg ≈ 80 mg x 10 Days |  |

Vaccinations put forward

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Vaccine | Type | Manufacturer | Dose | Effectiveness | Storage |
| Pfizer  (BNT162b2) | mRNA vaccine- | Pfizer, Inc., and BioNTech | 2 shots, 21 days apart | 95% against 1st strain.  (31) | 2-8℃ |
| Moderna | mRNA-1273 | ModernaTX, Inc. | 2 shots, one month (28 days) apart | 92-94.1% against 1st strain. (31)(32) | 2-8℃ for upto 30days. |
| Covaxin  (BBV154) | Inactivated virus | Bharat Biotech's BSL-3 | * 2 shots, one month (28 days) apart. (33) | 81% iterim efficacy against 1st strain | 2-8℃ |
| AstraZeneca  (Covishield, Vaxzevria) | Viral vector | Oxford university | 2 shots, 8-12weeks apart. | 79-85% against 1st strain | 2-8℃ for 6months |

\*mRNA vaccines teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies.(31)

Johnson & Johnson’s Janssen COVID-19 Vaccine: CDC and FDA have recommended a pause in the use of Johnson & Johnson’s J&J/Janssen COVID-19 Vaccine in the United States out of an abundance of caution as people who have received the J&J/Janssen COVID-19 Vaccine within the past three weeks developed severe headache, abdominal pain, leg pain, or shortness of breath should seek medical care right away.(34)

Vaccination and Incidence of infection

During the initial implementation phases, as for every new vaccine, post-introduction evaluations will be important to address many of the remaining questions about the performance of these vaccines. When a vaccine is used outside trial populations the effects of the vaccine may differ in specific geographies or subpopulations. Vaccine effectiveness (VE) might be different against various disease outcomes, against infection and infectiousness, and against newly emerging virus variant strains. Additionally, important programmatic issues will need to be addressed, such as the effectiveness of incomplete dose schedules, variation in dose intervals, and the interchangeability of different vaccine products. Suboptimal cold chain capacity, and off-schedule and incomplete delivery of doses could lead to different vaccine performance. Vaccines might not be as effective against new variants. Finally, assessing the duration of vaccine protection requires longer term studies.(35)

Complications of Covid 19

In population about 1 in 6,have been found to show complications. Many of these complications may be caused by a condition known as cytokine release syndrome or a cytokine storm. This is when an infection triggers your immune system to flood your bloodstream with inflammatory proteins called cytokines. They can kill tissue and damage your organs, including your lungs, heart, and kidneys.(36)

COVID-19 complications may include [Acute Respiratory Failure](https://www.webmd.com/lung/coronavirus-complications#1-2),[Pneumonia](https://www.webmd.com/lung/coronavirus-complications#1-3),[Acute Respiratory Distress Syndrome (ARDS)](https://www.webmd.com/lung/coronavirus-complications#1-4),[Acute Liver Injury](https://www.webmd.com/lung/coronavirus-complications#1-5),[Acute Cardiac Injury](https://www.webmd.com/lung/coronavirus-complications#2-6),[Secondary Infection](https://www.webmd.com/lung/coronavirus-complications#2-7),[Acute Kidney Injury](https://www.webmd.com/lung/coronavirus-complications#2-8),[Septic Shock](https://www.webmd.com/lung/coronavirus-complications#2-9),[Disseminated Intravascular Coagulation](https://www.webmd.com/lung/coronavirus-complications#2-10),[Blood Clots](https://www.webmd.com/lung/coronavirus-complications#3-11),[Multisystem Inflammatory Syndrome in Children](https://www.webmd.com/lung/coronavirus-complications#3-12),[Chronic Fatigue](https://www.webmd.com/lung/coronavirus-complications#3-13),[Rhabdomyolysis](https://www.webmd.com/lung/coronavirus-complications#3-14).(36)(37)

Bibilography

1. WHO | Coronavirus disease (COVID-2019) R&D [Internet]. [cited 2020 Apr 1]. Available from: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/

2. Zu ZY, Jiang M Di, Xu PP, Chen W, Ni QQ, Lu GM, et al. Pr e ss In Pr e. 2019;2019.

3. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora ’ s Box — Another Novel Coronavirus. 2020;1293–5.

4. COVID-19 vs. Flu vs. Cold: Which One Do You Have? [Internet]. [cited 2021 May 19]. Available from: https://www.medicinenet.com/covid-19\_vs\_flu\_vs\_cold/article.htm

5. Sriram N, Mondal TR, Reddy CM, Bagh SK. I nternational J ournal of A llied M edical S ciences and C linical R esearch ( IJAMSCR ) A review on novel Corona virus. 2020;8(1):14–20.

6. Coronavirus disease (COVID-19): Similarities and differences with influenza [Internet]. [cited 2021 May 19]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza

7. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. [cited 2020 Apr 11]; Available from: https://academic.oup.com/nsr/advance-article-abstract/doi/10.1093/nsr/nwaa036/5775463

8. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe [Internet]. 2020 Mar 11 [cited 2020 Apr 11];27(3):325–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32035028

9. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect Dis Poverty. 2020;9(1):1–12.

10. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) [Internet]. StatPearls. StatPearls Publishing; 2020 [cited 2020 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32150360

11. Fehr AR, Perlman S. HHS Public Access. 2016;1–23.

12. Coronavirus disease (COVID-19) [Internet]. [cited 2021 Apr 17]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjwjuqDBhAGEiwAdX2cj8RM6ZZ\_t3yXvE4Ytt8QvYT4VYylOCvVMk1H9epi7-igjTB5DI69mhoCn\_4QAvD\_BwE

13. Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol. 1990;64(11):5367–75.

14. Connell L. Library Guides: Harvard Referencing: Lecture notes.

15. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. 2020 [cited 2020 Apr 11]; Available from: www.elsevier.com/locate/jautimm

16. (No Title). 2020;

17. Elsevier Enhanced Reader [Internet]. [cited 2021 May 1]. Available from: https://reader.elsevier.com/reader/sd/pii/S2452014421000492?token=7A54C695644DC2883E6C7F0ADA1E4722DD87D623E66BAFD1296E63F1FC4B33F2627A9DD4851B1A7B68545BA9CD69677D&originRegion=eu-west-1&originCreation=20210501032229

18. Covid strain: Bangalore Corona samples show 11 mutations each; virus mutating faster than before | India News - Times of India [Internet]. [cited 2021 May 1]. Available from: https://timesofindia.indiatimes.com/india/covid-bluru-samples-show-11-mutations-each-virus-mutating-faster-than-before/articleshow/81333377.cms

19. Inside the COVID-19 mutant: The ‘drift’ of a virus [Internet]. [cited 2021 May 1]. Available from: https://www.businesstoday.in/bt-buzz/news/inside-the-covid-19-mutant-the-drift-of-a-virus/story/425695.html

20. New Covid strain in Singapore: What we know so far about B.1.617 variant affecting children [Internet]. [cited 2021 May 25]. Available from: https://www.livemint.com/science/health/new-covid-strain-in-singapore-what-we-know-so-far-about-b-1-617-variant-affecting-children-11621358293334.html

21. Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021 Jul 1;595(7865):17–8.

22. Vaccines highly effective against B.1.617.2 variant after 2 doses - GOV.UK [Internet]. [cited 2021 Jul 7]. Available from: https://www.gov.uk/government/news/vaccines-highly-effective-against-b-1-617-2-variant-after-2-doses

23. Bhatnagar T, Murhekar M, Soneja M, Gupta N, Giri S, Wig N, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J Med Res [Internet]. 2020 [cited 2020 Jul 22];0(0):0. Available from: http://www.ijmr.org.in/preprintarticle.asp?id=280484;type=0

24. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med [Internet]. 2020 May 7 [cited 2020 Jul 22];382(19):1787–99. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2001282

25. Valentin F, Gurabo R. Lopinavir / Ritonavir and COVID-19. 2020;(April).

26. Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study - Reuters [Internet]. [cited 2020 Jul 30]. Available from: https://in.reuters.com/article/health-coronavirus-roche-hldg/roche-rheumatoid-arthritis-drug-fails-to-help-covid-19-patients-in-italian-study-idINKBN23P1WM

27. What’s new | Coronavirus Disease COVID-19 [Internet]. [cited 2020 Jul 30]. Available from: https://www.covid19treatmentguidelines.nih.gov/whats-new/

28. Gupta AK, Parker BM, Priyadarshi V, Parker J. Cardiac Adverse Events With Remdesivir in COVID-19 Infection. Cureus [Internet]. 2020 Oct 24 [cited 2021 Apr 15];12(10). Available from: https://www.cureus.com/articles/44072-cardiac-adverse-events-with-remdesivir-in-covid-19-infection

29. Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip. 2020 Jan 1;34(1):469–74.

30. Velavan TP, Meyer CG. The COVID-19 epidemic. 2020;25(3):278–80.

31. Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study | pfpfizeruscom [Internet]. [cited 2021 Apr 17]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious

32. Moderna COVID-19 Vaccine Overview and Safety | CDC [Internet]. [cited 2021 Apr 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html

33. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv. medRxiv; 2020.

34. Johnson & Johnson’s Janssen COVID-19 Vaccine Overview and Safety | CDC [Internet]. [cited 2021 Apr 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html

35. Evaluation of COVID-19 vaccine effectiveness [Internet]. [cited 2021 May 16]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine\_effectiveness-measurement-2021.1

36. What Are the Complications of Coronavirus (COVID-19)? [Internet]. [cited 2021 May 25]. Available from: https://www.webmd.com/lung/coronavirus-complications#1

37. Certain Medical Conditions and Risk for Severe COVID-19 Illness | CDC [Internet]. [cited 2021 May 25]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html